Aster DM Quality Care Ltd (ASTERDM) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Aster DM Quality Care Ltd enters its first quarter as a merged entity, following the formal integration of Quality Care India Ltd on July 1, 2026. Investors are looking to the Q1 results to gauge the initial impact of recent greenfield hospital commissioning and the sustainability of high-margin specialty growth.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 1,182 Cr |
| Previous quarter PAT | Rs. 140 Cr |
| Previous quarter EBITDA margin | 20.7% |
| Market cap | Rs. 71,646.95 Cr |
| CMP | Rs. 822.15 |
Aster DM Quality Care Ltd Q1 Results Date and Time
The board meeting is scheduled for August 05, 2026, to consider the audited financial results.
What to expect from Aster DM Quality Care Ltd's Q1 FY27 results
Management's forward-looking thesis centers on sustaining double-digit volume growth following the flat performance seen in Q1 FY26, with seasonal tailwinds from vector-borne disease hospitalizations providing a structural floor for occupancy. The commissioning of 634 new beds in April 2026 across Ramesh Ongole, Whitefield Block D, and Capital Trivandrum represents a significant expansion, though these units are expected to carry initial ramp-up losses during the quarter.
The company continues to prioritize its CONGO-T specialty mix, which reached 58.7% in FY26, alongside a robust Cash & Insurance payor mix that hit 83% in the previous quarter. With the merger effective July 1, 2026, the upcoming call will focus on the first month of combined operations and the early realization of synergy potential from procurement and supply chain optimization.
Management has guided for annual maintenance capex at 5% of revenue, and investors will monitor if the recent credit rating upgrades to AA+/Stable provide a meaningful reduction in financing costs for the ongoing expansion pipeline.
Key Things To Watch
Performance vs Guidance Tracking
- Revenue growth — 16-17% in FY26 — 12% actual (standalone)
- ARPP IP growth — 7-8% over 2-3 years — 9% actual in Q4 FY26
- Bed additions — 878 in FY27 (merged) — 234 beds operationalized in April 2026
Greenfield Ramp-up Status
- Capital Trivandrum (454 beds), Ramesh Ongole (75 beds), and Whitefield Block D (159 beds) operationalized in April 2026
- Monitor pre-operative losses and timeline to breakeven relative to Nagercoil benchmark of 28.5% EBITDA margin within six quarters
Merger Integration and Synergies
- First quarter including QCIL operations (effective July 1, 2026)
- Targeting EBITDA upside of 10-15% of FY24 pro-forma EBITDA from procurement and supply chain optimization
Operating Metric Trajectory
- Volume recovery: Q1 FY26 saw flat IP growth; monitoring for return to double-digit growth
- CONGO-T mix: Target of 60-65% (58.7% achieved in FY26)
- MVT sustainability: 41% YoY growth in Q4 FY26
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
What is the status of the merger with Quality Care India Ltd?
The merger was approved by NCLT on June 19, 2026, and became effective on July 1, 2026. The combined entity, now named Aster DM Quality Care Ltd, operates 39 hospitals with over 10,600 beds.
How did Aster's standalone India business perform in its most recent quarter?
In Q4 FY26, the standalone India business reported revenue of Rs. 1,182 Cr, representing 18% YoY growth. Operating EBITDA reached Rs. 244 Cr with a margin of 20.7%.
Is the company on track with its ARPP IP growth guidance?
The company targeted ARPP IP growth of 7-8% over 2-3 years, and Q4 FY26 actual growth was 9% YoY. Management continues to focus on this metric as a key indicator of clinical complexity.
Related
- Aster DM Quality Care Ltd (ASTERDM) Q1 FY27 Results Analysis: PAT Falls 25%, Revenue Surges 22%Q1 FY2026-2027 Results Analysis
- Aster DM Quality Care Ltd (ASTERDM) Q1 FY27 Earnings Call: Revenue Up 20% YoY, Guides 24-25% EBITDA MarginQ1 FY2026-2027 Earnings Call
- Aster DM Healthcare Ltd Q4 FY26 Results Analysis: PAT Surges 77%, EBITDA Margin Expands 314 bpsQ4 FY2025-2026 Analysis